Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.13 +0.19 (+0.76%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Via The Motley Fool
Pfizer Unusual Options Activity For November 20
Via Benzinga
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
According to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry. 
Via Benzinga
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Via The Motley Fool
Stock Of The Day: Is Pfizer Set Up To Rally?
Shares of Pfizer (PFE) may be about to reverse and head higher. They are both oversold and at a support level. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Pfizer
Via Benzinga
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies. 
Via Benzinga
2 High-Yield Dividend Stocks I Can't Stop Buying
Via The Motley Fool
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about. 
Via MarketBeat
Friday's Top 5 Trending Stocks: What's The Scoop On Palantir, Bloom Energy, Pfizer?
Here's a look at Pfizer, Applied Materials, Bloom Energy, Palantir and FuelCell Energy. Friday's Top 5 Trending Stocks. 
Via Benzinga
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
Exposures Political
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention. 
Via Benzinga
Topics Government
Exposures Political
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
US Stocks Likely To Open In Red After Jerome Powell Says No Need To Be 'In A Hurry' On Rate Cuts: Tesla, TSMC And Domino's In Focus
U.S. stocks could open on a negative note on Friday after the Federal Reserve chair Jerome Powell's comments on Thursday that the economy is showing enough strength that there is no need to be "in a... 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
Palantir, Moderna, Pfizer, Alibaba, Tesla: Why These 5 Stocks Are On Investors' Radars Today
US stock market experienced a downward trend on Thursday, with both the Nasdaq Composite and the S&P 500 indices falling by nearly 0.6% respectively. 
Via Benzinga
Topics Stocks
Exposures US Equities
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks. 
Via Benzinga
Topics Government
Exposures Political
The Oncology Bet Is Already Paying Off For Pfizer
With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%... 
Via Benzinga
Exposures COVID-19
Bird Flu Puts Teen In Critical Condition As Canada Reports First Human Case: What You Need To Know
Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective COVID-19 vaccines. 
Via Benzinga
Exposures COVID-19
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture. Let’s take a closer look at the transactions for those interested in trading like the insiders. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
2 Magnificent S&P 500 Dividend Stocks Down Year to Date to Buy and Hold Forever
More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over upcoming COVID and RSV sales. 
Via Benzinga
Topics Earnings
Exposures COVID-19 Financial
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.